Company & Sponsor Intelligence
Bial - Portela C S.A.
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials16
Recruiting0
Completed16
Countries6
Therapeutic footprint
epilepsyparkinsons
Indexed studies
NCT02777671Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Gliclazide in Healthy Volunteers
epilepsy · PortugalPHASE1
epilepsy · PortugalPHASE1
NCT02283814A Open-label, Drug Interaction Study Between Eslicarbazepine Acetate and Topiramate
epilepsy · PHASE1
epilepsy · PHASE1
NCT01519284Study of BIA 9-1067 to Investigate Its Effect on Levodopa Pharmacokinetic
parkinsons · PortugalPHASE1
parkinsons · PortugalPHASE1
NCT02071823Comparative Bioavailability Study of BIA 9-1067 25 mg Capsules
parkinsons · CanadaPHASE1
parkinsons · CanadaPHASE1
NCT02172742The Effect of BIA 2-093 on the Steady-state Pharmacokinetics of Digoxin
epilepsy · PortugalPHASE1
epilepsy · PortugalPHASE1
NCT01879332A Sequential Multiple Ascending Dose Study of the Safety and Pharmacokinetics of Eslicarbazepine Acetate in Adult Healthy Volunteers
epilepsy · United StatesPHASE1
epilepsy · United StatesPHASE1
NCT03116308Effect of Food on Opicapone
parkinsons · PHASE1
parkinsons · PHASE1
NCT03091543Tolerability, Safety and Pharmacokinetics of Four Single-doses of BIA 6-512 (Trans-resveratrol) and Their Effect on the Levodopa Pharmacokinetics
parkinsons · PortugalPHASE1
parkinsons · PortugalPHASE1
NCT02170077A Placebo-controlled Study to Investigate Safety and Efficacy of BIA 2-093
epilepsy · PortugalPHASE2
epilepsy · PortugalPHASE2
NCT02283827Open-label Drug Interaction Study Between Eslicarbazepine Acetate and Phenytoin.
epilepsy · PHASE1
epilepsy · PHASE1
NCT02763852Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Benserazide (100/25 mg)
parkinsons · PortugalPHASE1
parkinsons · PortugalPHASE1
NCT03820037Relative Bioavailability and Bioequivalence of Opicapone
parkinsons · United KingdomPHASE1
parkinsons · United KingdomPHASE1
Intelligence layer updated: 2026-10-14 06:11:28.884102+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →